Literature DB >> 12623269

Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis.

V Gruppo1, I M Orme.   

Abstract

It is generally agreed that BCG vaccination is relatively ineffective in adults exposed to tuberculosis infection. The reasons for this may well be multiple, and may include the possibility that higher doses of BCG may induce a mixed TH1 and TH2 response, which may lessen the protective effect of the vaccine. To test this hypothesis, mice were vaccinated with a range of doses of BCG and then challenged by the intravenous or aerogenic routes with virulent Mycobacterium tuberculosis. While the data support the hypothesis that a TH2 response is induced by higher doses of BCG, this was found to have no influence whatsoever on the capacity of the vaccinated mouse to express acquired specific resistance to the challenge infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12623269     DOI: 10.1054/tube.2002.0340

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  15 in total

1.  Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

Authors:  Nacho Aguilo; Ana Maria Toledo; Eva Maria Lopez-Roman; Esther Perez-Herran; Eamonn Gormley; Joaquin Rullas-Trincado; Iñigo Angulo-Barturen; Carlos Martin
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

2.  Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model.

Authors:  S M Irwin; A Goodyear; A Keyser; R Christensen; J M Troudt; J L Taylor; A Bohsali; V Briken; A A Izzo
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

3.  Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.

Authors:  Evelyn Guirado; Olga Gil; Neus Cáceres; Mahavir Singh; Cristina Vilaplana; Pere-Joan Cardona
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

4.  Correlates of Vaccine-Induced Protection against Mycobacterium tuberculosis Revealed in Comparative Analyses of Lymphocyte Populations.

Authors:  Sherry L Kurtz; Karen L Elkins
Journal:  Clin Vaccine Immunol       Date:  2015-08-12

5.  Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis.

Authors:  Hans-Willi Mittrücker; Ulrich Steinhoff; Anne Köhler; Marion Krause; Doris Lazar; Peggy Mex; Delia Miekley; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

6.  Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology.

Authors:  J A Tree; A Williams; S Clark; G Hall; P D Marsh; J Ivanyi
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

7.  Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.

Authors:  Angela M Minassian; Edward O Ronan; Hazel Poyntz; Adrian V S Hill; Helen McShane
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

8.  Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.

Authors:  Suraj B Sable; Mani Cheruvu; Subhadra Nandakumar; Sunita Sharma; Kakali Bandyopadhyay; Kathryn L Kellar; James E Posey; Bonnie B Plikaytis; Rama Rao Amara; Thomas M Shinnick
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

9.  A randomised controlled trial of the effects of albendazole in pregnancy on maternal responses to mycobacterial antigens and infant responses to Bacille Calmette-Guérin (BCG) immunisation [ISRCTN32849447].

Authors:  Alison M Elliott; Proscovia B Namujju; Patrice A Mawa; Maria A Quigley; Margaret Nampijja; Peter M Nkurunziza; John T Belisle; Moses Muwanga; James A G Whitworth
Journal:  BMC Infect Dis       Date:  2005-12-21       Impact factor: 3.090

10.  Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.

Authors:  Elma Z Tchilian; Christiane Desel; Emily K Forbes; Silke Bandermann; Clare R Sander; Adrian V S Hill; Helen McShane; Stefan H E Kaufmann
Journal:  Infect Immun       Date:  2008-12-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.